Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ...

Court filings give insight into why shooting suspect Louis Mangione might have targeted the UnitedHealthcare executive: "It checks every box." In other news: Hospital construction trends include AI; ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Billions of dollars worth of U.S. biomanufacturing plant development has been announced, and site selection will likely be ...